CelLBxHealth has completed an oversubscribed US$10.9 million fundraise

December 2025 — CelLBxHealth has completed an oversubscribed US$10.9 million fundraise comprising a placing, subscription and retail offer.

CelLBxHealth is a specialist diagnostics company. Its proprietary Parsortix® technology can capture and harvest very rare cells, including circulating tumor cells (CTCs), from a blood sample. Parsortix has received FDA clearance for clinical use to guide precision cancer care.

Our role in the transaction

Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised and supported CelLBxHealth in its fundraise. The transaction was particularly challenging given the company’s previously disclosed funding runway into the first quarter of 2026, as well as the rapid onboarding of a new management team. The new team, led by Jan Groen and Peter Collins, was delighted by the level of support from existing holders alongside substantial interest from new investors. Notably, the company raised more than twice its market capitalization, with investor demand ultimately scaled back. The strength of participation reflects investor support for the company’s strategy, its new leadership and confidence in its core technology.

Servicio

Financiamiento, asesoramiento sobre la deuda y mercado de acciones

Partes

“We were delighted to see strong support in the fundraise from both existing shareholders and non-holders. This heavily oversubscribed funding gives us the much-needed capital to pursue our revised business strategy as we focus on the substantial market opportunity for the Parsortix platform. It was a pleasure working with Oaklins Cavendish, whose support helped bring all sides of the business together to deliver a successful fundraise despite very challenging circumstances. We look forward to significant commercial progress in 2026 and beyond.”

Peter Collins

Interim CEO, CelLBxHealth

Contáctese con el equipo de la transacción

Geoff Nash

Director

Londres, Reino Unido
Oaklins Cavendish

Ver perfil Ponte en contacto

Transacciones relacionadas

Heka Dental has joined forces with Impilo to anchor focused buy-and-build strategy

Private Equity | Salud

Heka Dental has joined forces with Impilo to anchor focused buy-and-build strategy

Heka Dental, a leading Danish designer and manufacturer of premium dental treatment units, has been acquired by the Swedish private equity firm Impilo. The acquisition establishes Heka Dental as a strategic platform for consolidation in the European dental equipment market. Impilo will execute a focused buy-and-build strategy to accelerate growth and expand its footprint across Europe.

Conozca más

itemedical has been acquired by Halma

Salud | TMT

itemedical has been acquired by Halma

itemedical, a Netherlands-based provider of digital platforms that integrate real-time patient data and alarms from a wide range of medical devices to support clinical decision-making and workflow efficiency in hospitals, has been acquired by Halma plc, a global group of life-saving technology companies. The acquisition represents a milestone in itemedical’s development and provides a platform for its next phase of growth. By joining Halma’s healthcare sector as a business unit of Halma subsidiary Static Systems Group (SSG), itemedical will strengthen its position as a provider of digital hospital workflow solutions, benefiting from access to a global network of technology businesses, resources to accelerate innovation and opportunities to expand its international footprint.

Conozca más

OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value

Private Equity | TMT

OEP Danzig BidCo has completed a mandatory tender offer for the shares of Digital Value

OEP Danzig BidCo S.p.A. has completed a mandatory tender offer for the shares of Digital Value S.p.A.

Conozca más